Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 9/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.37 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.36 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | CSF1R | P07333 | 1/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.33 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.33 |
| ▸ | CDK7 | P50613 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
| ▸ | HPGDS | O60760 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26573670 | 0.77 | FLT3 (0.39) | FDPSFLT3MAPK8HCAR3 | |
| SCHEMBL2844731 | 0.71 | ABL1 (0.52) | FLT3MAPK8ABL1LCKCSF1R | |
| SCHEMBL29256022 | 0.70 | BLM (0.37) | — | |
| SCHEMBL7987681 | 0.70 | HRH3 (0.40) | FLT3MAPK8HTR7 | |
| Carbamic Acid SCHEMBL2847023 | 0.69 | ABL1 (0.48) | FLT3MAPK8HCAR3ABL1LCK | |
| SCHEMBL15357779 | 0.68 | FLT3 (0.41) | FLT3MAPK8HCAR3ABL1LCK | |
| SCHEMBL1967684 | 0.66 | SRC (0.44) | FDPS | |
| SCHEMBL12356602 | 0.66 | FLT3 (0.40) | FLT3MAPK8HCAR3ABL1LCK | |
| SCHEMBL10212545 | 0.66 | HRH4 (0.55) | HRH4 | |
| SCHEMBL1774897 | 0.66 | GAA (0.42) | FLT3MAPK8HCAR3ABL1LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES AG (AT) | 2014-11-27 | — | — | US | disclosed |
| EP-2674161-A1 | FMO3 inhibitors for treating pain | Akron Molecules GmbH (AT) | 2013-12-18 | — | — | EP | disclosed |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | AKRON MOLECULES GMBH (AT) | 2013-09-26 | — | — | US | disclosed |
| EP-2637649-A2 | COMPOUNDS AND METHODS FOR TREATING PAIN | Akron Molecules GmbH (AT) | 2013-09-18 | — | — | EP | disclosed |
| WO-2012062925-A2 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES GMBH (AT) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | TRPV1, ACHE, OPRL1 | FDPS 736/4885FLT3 2439/4885MAPK8 3552/4885 |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | TRPV1, ACHE, OPRL1 | FDPS 736/4885FLT3 2439/4885MAPK8 3552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.